Source comparison
Half-Life Comparison and Experimental Dosing Implications
The pharmacokinetic difference between the two forms is stark: CJC-1295 with DAC DAC-GRF 5.8 – 8.1 days Once or twice weekly CJC-1295 without DAC Modified GRF (1-29) ~30 minutes Multiple times daily For context, other GHRH analogs fall well below even the with
This comparison does not assign a generated winner or score.
- The pharmacokinetic difference between the two forms is stark:
- CJC-1295 with DAC
- DAC-GRF
- 5.8 – 8.1 days
- Once or twice weekly
- CJC-1295 without DAC
- Modified GRF (1-29)
- ~30 minutes
- Multiple times daily
- For context, other GHRH analogs fall well below even the without-DAC form: sermorelin has a half-life of 10-12 minutes, and tesa sits at approximately 30 minutes. Researchers can review tesa peptide benefits and pharmacology for a useful comparative baseline.
- The without-DAC form is often preferred in protocols that require tight temporal control over GH pulses. Its short window allows researchers to time injections around specific assay windows, mimicking the body's natural ultradian GH rhythm. The DAC form, by contrast, produces a sustained elevation that is better suited to protocols measuring cumulative IGF-1 response over days.
- For researchers building multi-peptide stacks, the sermorelin, ipamorelin, and CJC-1295 combination overview provides useful context on how different half-lives interact within the same protocol.